SEC Form 4 · accession 0001567619-18-003784
KalVista Pharmaceuticals, Inc. · KALV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward W Unkart
Director
Period of report
Oct 3, 2018
Accepted (ET)
Oct 5, 2018 · 6:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F1 | $22.65 | Oct 3, 2018 | A | 7,000 | A | — | Oct 2, 2028 | Common Stock | 7,000 | 7,000 | D |
Explanation of responses
- F1The option vests over a 12 month period: 1/12th on November 3, 2018, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.